Vogenx, Inc.: Vogenx Announces Pricing of Initial Public Offering
Vogenx, Inc. (NASDAQ:VOGX) priced its initial public offering of 6,250,000 shares at $13.00 per share, the high end of the range, with gross proceeds expected at about $81.3 million. Shares will begin trading on Nasdaq on Aug. 12, 2026, and the deal is expected to close Aug. 13. Underwriters have a 45-day option for up to 937,500 additional shares.
How this was made
The 30-second read
Why it matters
The company’s IPO is priced at $13.00 per share at the high end of the range, raising about $81.3M gross proceeds, and the stock is set to begin trading on Nasdaq on Aug 12, 2026.
Market read
This is a primary IPO mechanics update for VOGX, giving traders the offer price, share count, expected proceeds, and the first trading date.
What to watch
No details are provided on lockup expirations, insider ownership, or use of proceeds timing, which can materially affect post-IPO trading beyond the offer mechanics.
Background
Vogenx is a clinical-stage biopharmaceutical company developing mizagliflozin for post-bariatric hypoglycemia and gastroparesis, among other metabolic-related indications.
Ticker impact
Vogenx priced its IPO at $13.00 per share, with 6.25M shares sold and expected $81.3M gross proceeds, starting Nasdaq trading Aug 12.
Likely initial volatility around the first Nasdaq open, with direction driven by IPO demand versus dilution from the new shares.
The article discloses concrete IPO terms (price, share count, proceeds) and the first trading date, but provides no valuation, lockup, or post-IPO guidance to refine direction beyond typical IPO flow effects.
Market effects
Adds another clinical-stage biopharma IPO to the market, which can marginally affect sentiment toward early-stage biotech fundraising.
Limited, as the event is company-specific and not tied to a regional macro catalyst.
Low, as this is a US-listed IPO with no stated international regulatory or commercial linkage beyond the company’s licensing footprint.
Counterpoint
High-end IPO pricing can still lead to weak aftermarket performance if demand was strong only at the offer price and the stock opens with heavy supply.
Key entities
- companyVogenx, Inc.
Clinical-stage biopharmaceutical company pricing its IPO and preparing to list on Nasdaq under VOGX.
- product_candidateMizagliflozin
Lead product candidate in development for PBH and gastroparesis.
- financial_institutionJonesTrading Institutional Services LLC
Named as sole book-running manager for the offering.
- regulatorSEC
Registration statement declared effective on Aug 11, 2026.
